Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
-
Multicenter Study Comparative Study Clinical Trial
Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
To examine the cost-effectiveness of using recombinant human erythropoietin (rHuEPO) to reduce red blood cells (RBC) transfusions in intensive care unit (ICU) patients. ⋯ rHuEPO appears to be cost-effective for reducing RBC transfusions in heterogeneous ICU populations, assuming RBC transfusions increase the risk of nosocomial bacterial infections.